A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure |
| |
| Authors: | Dargie Henry J Hildebrandt Per R Riegger Günter A J McMurray John J V McMorn Stephen O Roberts Jeremy N Zambanini Andrew Wilding John P H |
| |
| Affiliation: | Department of Cardiology, Western Infirmary, Glasgow, Scotland. H.Dargie@bio.gla.ac.uk |
| |
| Abstract: | |
| |
| Keywords: | BNP, brain natriuretic peptide CHF, chronic heart failure ECHO, echocardiogram/echocardiography EE, efficacy evaluable ITT, intent-to-treat with last observation carried forward LVEDVI, left ventricular end-diastolic volume index LVEF, left ventricular ejection fraction LVESVI, left ventricular end-systolic volume index LVMI, left ventricular mass index NYHA, New York Heart Association PLB, placebo RSG, rosiglitazone T2DM, type 2 diabetes mellitus |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
